Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia-related infection.
J J
JJ
Lee
I J
IJ
Chung
Y K
YK
Ahn
M R
MR
Park
D H
DH
Shin
J G
JG
Cho
H J
HJ
Kim
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002951:Citrates / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects; D006098:Granulocytes / Q000637:transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D007239:Infections / Q000628:therapy*; D007937:Leukapheresis; D004915:Leukemia, Erythroblastic, Acute / Q000150:complications* / Q000188:drug therapy; D017708:Leukocyte Transfusion / Q000009:adverse effects*; D008297:Male; D009503:Neutropenia / Q000209:etiology / Q000628:therapy*; D000077559:Sodium Citrate; D013617:Tachycardia, Supraventricular / Q000209:etiology*
D000925:Anticoagulants; D002951:Citrates; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000077559:Sodium Citrate; C015019:enocitabine; D015255:Idarubicin